Abstract
Gastric cancer remains difficult to cure and has a poor overall prognosis. Chemotherapy and multimodality therapy has shown some benefit in the treatment of gastric cancer. Current therapies for gastric cancer have their limitations; thus, we are in need of newer treatment options including targeted therapies. Here, we review the biologic therapy with trastuzumab in human epidermal growth factor receptor 2 (HER2)+ gastric cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 143-151 |
Number of pages | 9 |
Journal | Therapeutic Advances in Medical Oncology |
Volume | 5 |
Issue number | 2 |
DOIs | |
State | Published - Mar 2013 |
Keywords
- gastric cancer
- trastuzumab
ASJC Scopus subject areas
- Oncology